Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune said it has reached an agreement with the FDA to resubmit its marketing application for its experimental skin cancer drug after the regulator twice declined approval. The update reduces some regulatory uncertainty, but the drug still faces another review cycle before any commercial launch. The news is modestly supportive for shares, though the eventual outcome remains uncertain.

Analysis

Replimune said it has reached an agreement with the FDA to resubmit its marketing application for its experimental skin cancer drug after the regulator twice declined approval. The update reduces some regulatory uncertainty, but the drug still faces another review cycle before any commercial launch. The news is modestly supportive for shares, though the eventual outcome remains uncertain.